Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive Clinical Trial

Official title:
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)

Clinical Trial Details — Status: Completed

Administrative data
NCT number	NCT01126437
Other study ID #	205.452
Secondary ID	2009-015713-51
Status	Completed
Phase	Phase 3
First received	May 6, 2010
Last updated	May 20, 2014
Start date	May 2010
Est. completion date	May 2013

Study information
Verified date	May 2014
Source	Boehringer Ingelheim
Contact	n/a
Is FDA regulated	No
Health authority	Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia MedicaAustralia: Dept of Health and Ageing Therapeutic Goods AdminAustria: Medicines and Medical Devices AgencyBelgium: Federal Agency for Medicinal and Health ProductsBrazil: National Health Surveillance AgencyBulgaria: Bulgarian Drug AgencyCanada: Health CanadaChina: Food and Drug AdministrationColumbia: Instituto Nacional de Vigilancia de Medicamentos y AlimentosCroatia: Agency for Medicinal Product and Medical DevicesDenmark: Danish Medicines AgencyFinland: Finnish Medicines AgencyFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Georgia: Ministry of HealthGermany: Federal Institute for Drugs and Medical DevicesGreece: Ethics CommitteeGuatemala: Ministry of Public Health and Social AssistanceHungary: National Institute of PharmacyIndia: Drugs Controller General of IndiaIreland: Irish Medicines BoardIsrael: Israeli Health Ministry Pharmaceutical AdministrationItaly: Ethics CommitteeLatvia: State Agency of MedicinesLithuania: State Medicine Control Agency - Ministry of HealthMalaysia: Ministry of HealthMexico: Federal Commission for Sanitary Risks ProtectionNetherlands: Central Committee Research Involving Human SubjectsNew Zealand: Multi-Regional Ethics CommitteeNorway: Norwegian Medicines AgencyPanama: Ministry of HealthPeru: General Directorate of Pharmaceuticals, Devices, and DrugsPhilippines: Bureau of Food and DrugsPoland: Registration Medicinal Product Medical Device Biocidal ProductPortugal: National Pharmacy and Medicines InstituteRomania: National Medicines AgencyRussia: Pharmacological Committee, Ministry of HealthSerbia and Montenegro: Agency for Drugs and Medicinal DevicesSlovakia: State Institute for Drug ControlSouth Africa: Medicines Control CouncilSouth Korea: Ministry of Food and Drug Safety (MFDS)Spain: Spanish Agency of MedicinesSweden: Medical Products AgencySwitzerland: SwissmedicTaiwan: Department of HealthThailand: Food and Drug AdministrationTunisia: Ministry of Public HealthTurkey: Ministry of HealthUkraine: State Pharmacological Center - Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited States: Food and Drug Administration
Study type	Interventional

Clinical Trial Summary

Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies. Therefore, prospective data from a trial of adequate size and duration is required to establish that compared to tiotropium HandiHaler®, tiotropium Respimat® will have (a) similar effects on safety and (b) similar or superior effects on exacerbations.

Recruitment information / eligibility
Status	Completed
Enrollment	17183
Est. completion date	May 2013
Est. primary completion date	May 2013
Accepts healthy volunteers	No
Gender	Both
Age group	40 Years and older
Eligibility	Inclusion criteria: 1. All patients must sign an informed consent consistent with International Conference on Harmonization Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions. 2. Male or female patients 40 years of age or older. 3. Patients must be current or ex-smokers with a smoking history of =10 pack-years. (Patients who have never smoked cigarettes must be excluded) 4. All patients must have a diagnosis of COPD (P06-12085), and must meet the following criteria: Relatively stable airway obstruction with a post-bronchodilator FEV1 = 70% of predicted normal and post-bronchodilator FEV1 / FVC =70%. Pulmonary function tests (PFTs) were conducted after the inhalation of 400 µg salbutamol / albuterol (preferred), however testing with either 200 µg salbutamol/albuterol or a combination of salbutamol / albuterol with ipratropium bromide (2 to 4 actuations) was acceptable. Other short-acting beta agonists, such as terbutaline, may have been used for the testing. The medication used for the testing was documented. Further, historical data from measurements within the past 6 months either at the site or at a referral site may have been used (see Section 6.2.1 of the CTP, located in Appendix 16.1.1). Subjects were not to have been randomized to the study without the availability of spirometry data at the actual study site. Eligibility for PFT sub-study: For subjects participating in the spirometry sub-study, historical data may not have been used for inclusion. These subjects must have qualified in the clinic at Visit 1 after performing a baseline measurement. These subjects performed a pre-dose PFT which was followed by the administration of 400 µg salbutamol / albuterol only (no other short-acting beta agonist was allowed), followed by a post-dose PFT for qualification. 5. Able to inhale from the HandiHaler® and the Respimat® devices. Exclusion criteria: 1. Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence the patients ability to participate in the study. 2. Patients with a recent history (i.e., six months or less) of myocardial infarction. 3. Patients with any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year. 4. Hospitalisation for cardiac failure (New York Heart Association (NYHA) Class III or IV) during the past year. 5. Known active tuberculosis. 6. Patients with a history of asthma, cystic fibrosis, clinically evident bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease. 7. History of thoracotomy with pulmonary resection. Subjects with a history of thoracotomy for other reasons were to have been evaluated per exclusion criterion 1. 8. Subject was planning to undergo lung transplant or lung volume reduction surgery (LVRS). 9. Malignancy for which the subject had undergone resection, radiation, chemotherapy or biological treatments within the last 5 years. Subjects with treated basal cell carcinoma were allowed. 10. Known respiratory infection or exacerbation of COPD in the 4 weeks prior to randomization. 11. Known hypersensitivity to anticholinergic drugs, lactose, benzalkonium chloride (BAC), ethylenediaminetetraacetic acid (EDTA), or any other components of the HandiHaler® or Respimat® inhalation solution delivery system. 12. Known moderate to severe renal impairment (as judged by the investigator). 13. Known narrow angle glaucoma. 14. Known significant symptomatic prostatic hyperplasia or bladder-neck obstruction. Subjects whose symptoms were controlled on treatment may have been included. 15. Use of systemic corticosteroid medication at unstable doses (i.e., less than 6 weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone per day. 16. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception for at least 3 months prior to and for the duration of the trial. 17. Significant alcohol or drug abuse within the past 12 months. 18. Subjects requiring the use of supplemental oxygen therapy for > 12 hours per day. 19. Subjects who had completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit or subjects who were currently in a pulmonary rehabilitation program that was not maintained throughout the duration of the study. 20. Subjects who had taken an investigational drug within 30 days prior to the Screening Visit. 21. Previous participation (receipt of randomized treatment) in this study. 22. Subjects who were currently participating in an interventional study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Chronic Disease
Lung Diseases
Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• tiotropium 18 mcg
HandiHaler
• tiotropium 1.25 mcg (2 actuations/day)
soft mist inhaler 2 actuations=2 puffs/day
• tiotropium 2.5 mcg (2 actuations/day)
soft mist inhaler (2 actuations=2 puffs/day)

Locations
Country	Name	City	State
Argentina	205.452.54003 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	205.452.54011 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	205.452.54013 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	205.452.54027 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	205.452.54029 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	205.452.54031 Boehringer Ingelheim Investigational Site	Capital Federal
Argentina	205.452.54025 Boehringer Ingelheim Investigational Site	Florencio Varela
Argentina	205.452.54007 Boehringer Ingelheim Investigational Site	Mar del Plata
Argentina	205.452.54015 Boehringer Ingelheim Investigational Site	Mar del Plata
Argentina	205.452.54001 Boehringer Ingelheim Investigational Site	Mendoza
Argentina	205.452.54019 Boehringer Ingelheim Investigational Site	Monte Grande
Argentina	205.452.54005 Boehringer Ingelheim Investigational Site	Quilmes
Argentina	205.452.54009 Boehringer Ingelheim Investigational Site	Rosario
Argentina	205.452.54021 Boehringer Ingelheim Investigational Site	Rosario
Argentina	205.452.54017 Boehringer Ingelheim Investigational Site	San Miguel de Tucumán
Argentina	205.452.54023 Boehringer Ingelheim Investigational Site	San Miguel de Tucumán
Australia	205.452.61006 Boehringer Ingelheim Investigational Site	Adelaide	South Australia
Australia	205.452.61004 Boehringer Ingelheim Investigational Site	Box Hill	Victoria
Australia	205.452.61003 Boehringer Ingelheim Investigational Site	Footscray	Victoria
Australia	205.452.61001 Boehringer Ingelheim Investigational Site	Frankston	Victoria
Australia	205.452.61005 Boehringer Ingelheim Investigational Site	Nedlands	Western Australia
Australia	205.452.61002 Boehringer Ingelheim Investigational Site	Woodville	South Australia
Austria	205.452.43002 Boehringer Ingelheim Investigational Site	Feldbach
Austria	205.452.43003 Boehringer Ingelheim Investigational Site	Hallein
Austria	205.452.43005 Boehringer Ingelheim Investigational Site	Thalheim bei Wels
Belgium	205.452.32009 Boehringer Ingelheim Investigational Site	Godinne
Belgium	205.452.32007 Boehringer Ingelheim Investigational Site	Gozée
Belgium	205.452.32002 Boehringer Ingelheim Investigational Site	Halen
Belgium	205.452.32001 Boehringer Ingelheim Investigational Site	Leuven
Belgium	205.452.32006 Boehringer Ingelheim Investigational Site	Linkebeek
Belgium	205.452.32005 Boehringer Ingelheim Investigational Site	Merksem
Belgium	205.452.32008 Boehringer Ingelheim Investigational Site	Natoye
Belgium	205.452.32003 Boehringer Ingelheim Investigational Site	Tessenderlo
Belgium	205.452.32004 Boehringer Ingelheim Investigational Site	Zichem
Brazil	205.452.55005 Boehringer Ingelheim Investigational Site	Florianópolis
Brazil	205.452.55010 Boehringer Ingelheim Investigational Site	Passo Fundo - RS
Brazil	205.452.55001 Boehringer Ingelheim Investigational Site	Porto Alegre
Brazil	205.452.55002 Boehringer Ingelheim Investigational Site	Porto Alegre
Brazil	205.452.55003 Boehringer Ingelheim Investigational Site	Recife
Brazil	205.452.55004 Boehringer Ingelheim Investigational Site	Rio de Janeiro
Brazil	205.452.55011 Boehringer Ingelheim Investigational Site	Río de Janeiro
Brazil	205.452.55008 Boehringer Ingelheim Investigational Site	Sao Pablo
Brazil	205.452.55009 Boehringer Ingelheim Investigational Site	Sao Paulo
Brazil	205.452.55006 Boehringer Ingelheim Investigational Site	São Paulo
Brazil	205.452.55007 Boehringer Ingelheim Investigational Site	São Paulo
Bulgaria	205.452.35909 Boehringer Ingelheim Investigational Site	Plovdiv
Bulgaria	205.452.35910 Boehringer Ingelheim Investigational Site	Plovdiv
Bulgaria	205.452.35901 Boehringer Ingelheim Investigational Site	Sofia
Bulgaria	205.452.35902 Boehringer Ingelheim Investigational Site	Sofia
Bulgaria	205.452.35903 Boehringer Ingelheim Investigational Site	Sofia
Bulgaria	205.452.35904 Boehringer Ingelheim Investigational Site	Sofia
Bulgaria	205.452.35905 Boehringer Ingelheim Investigational Site	Sofia
Bulgaria	205.452.35908 Boehringer Ingelheim Investigational Site	Sofia
Bulgaria	205.452.35914 Boehringer Ingelheim Investigational Site	Sofia
Bulgaria	205.452.35915 Boehringer Ingelheim Investigational Site	Sofia
Bulgaria	205.452.35912 Boehringer Ingelheim Investigational Site	Stara Zagora
Bulgaria	205.452.35906 Boehringer Ingelheim Investigational Site	Veliko Turnovo
Canada	205.452.11030 Boehringer Ingelheim Investigational Site	Burlington	Ontario
Canada	205.452.11015 Boehringer Ingelheim Investigational Site	Calgary	Alberta
Canada	205.452.11032 Boehringer Ingelheim Investigational Site	Calgary	Alberta
Canada	205.452.11042 Boehringer Ingelheim Investigational Site	Corunna	Ontario
Canada	205.452.11049 Boehringer Ingelheim Investigational Site	Courtice	Ontario
Canada	205.452.11004 Boehringer Ingelheim Investigational Site	Downsview	Ontario
Canada	205.452.11028 Boehringer Ingelheim Investigational Site	Edmonton	Alberta
Canada	205.452.11037 Boehringer Ingelheim Investigational Site	Edmonton	Alberta
Canada	205.452.11045 Boehringer Ingelheim Investigational Site	Edmonton	Alberta
Canada	205.452.11047 Boehringer Ingelheim Investigational Site	Edmonton	Alberta
Canada	205.452.11044 Boehringer Ingelheim Investigational Site	Grand Falls-Windsor	Newfoundland and Labrador
Canada	205.452.11007 Boehringer Ingelheim Investigational Site	Greenfield Park	Quebec
Canada	205.452.11009 Boehringer Ingelheim Investigational Site	Hamilton	Ontario
Canada	205.452.11029 Boehringer Ingelheim Investigational Site	Hamilton	Ontario
Canada	205.452.11050 Boehringer Ingelheim Investigational Site	Hamilton	Ontario
Canada	205.452.11048 Boehringer Ingelheim Investigational Site	Kelowna	British Columbia
Canada	205.452.11040 Boehringer Ingelheim Investigational Site	Kingston	Ontario
Canada	205.452.11005 Boehringer Ingelheim Investigational Site	La Malbaie	Quebec
Canada	205.452.11035 Boehringer Ingelheim Investigational Site	London	Ontario
Canada	205.452.11006 Boehringer Ingelheim Investigational Site	Longueuil	Quebec
Canada	205.452.11051 Boehringer Ingelheim Investigational Site	Maple Ridge	British Columbia
Canada	205.452.11001 Boehringer Ingelheim Investigational Site	Mississauga	Ontario
Canada	205.452.11054 Boehringer Ingelheim Investigational Site	Mississauga	Ontario
Canada	205.452.11033 Boehringer Ingelheim Investigational Site	Moncton	New Brunswick
Canada	205.452.11043 Boehringer Ingelheim Investigational Site	Montreal	Quebec
Canada	205.452.11053 Boehringer Ingelheim Investigational Site	Mount Pearl	Newfoundland and Labrador
Canada	205.452.11022 Boehringer Ingelheim Investigational Site	Newmarket	Ontario
Canada	205.452.11024 Boehringer Ingelheim Investigational Site	Ottawa	Ontario
Canada	205.452.11013 Boehringer Ingelheim Investigational Site	Point Claire	Quebec
Canada	205.452.11031 Boehringer Ingelheim Investigational Site	Quebec
Canada	205.452.11027 Boehringer Ingelheim Investigational Site	Richmond Hill	Ontario
Canada	205.452.11010 Boehringer Ingelheim Investigational Site	Saint John	New Brunswick
Canada	205.452.11041 Boehringer Ingelheim Investigational Site	Sarnia	Ontario
Canada	205.452.11003 Boehringer Ingelheim Investigational Site	Saskatoon	Saskatchewan
Canada	205.452.11011 Boehringer Ingelheim Investigational Site	Saskatoon	Saskatchewan
Canada	205.452.11036 Boehringer Ingelheim Investigational Site	Saskatoon	Saskatchewan
Canada	205.452.11039 Boehringer Ingelheim Investigational Site	Saskatoon	Saskatchewan
Canada	205.452.11018 Boehringer Ingelheim Investigational Site	Sherbrooke	Quebec
Canada	205.452.11002 Boehringer Ingelheim Investigational Site	Spruce Grove	Alberta
Canada	205.452.11017 Boehringer Ingelheim Investigational Site	St. John's	Newfoundland and Labrador
Canada	205.452.11021 Boehringer Ingelheim Investigational Site	St. John's	Newfoundland and Labrador
Canada	205.452.11020 Boehringer Ingelheim Investigational Site	St. Lambert	Quebec
Canada	205.452.11019 Boehringer Ingelheim Investigational Site	Toronto	Ontario
Canada	205.452.11034 Boehringer Ingelheim Investigational Site	Toronto	Ontario
Canada	205.452.11052 Boehringer Ingelheim Investigational Site	Toronto	Ontario
Canada	205.452.11026 Boehringer Ingelheim Investigational Site	Trois-Rivieres	Quebec
Canada	205.452.11014 Boehringer Ingelheim Investigational Site	Vancouver	British Columbia
Canada	205.452.11016 Boehringer Ingelheim Investigational Site	Vancouver	British Columbia
Canada	205.452.11012 Boehringer Ingelheim Investigational Site	Windsor	Ontario
Canada	205.452.11025 Boehringer Ingelheim Investigational Site	Winnipeg	Manitoba
China	205.452.86009 Boehringer Ingelheim Investigational Site	Beijing
China	205.452.86010 Boehringer Ingelheim Investigational Site	Beijing
China	205.452.86011 Boehringer Ingelheim Investigational Site	Beijing
China	205.452.86012 Boehringer Ingelheim Investigational Site	Beijing
China	205.452.86038 Boehringer Ingelheim Investigational Site	Beijing
China	205.452.86026 Boehringer Ingelheim Investigational Site	Changchun
China	205.452.86024 Boehringer Ingelheim Investigational Site	Changsha
China	205.452.86025 Boehringer Ingelheim Investigational Site	Changsha
China	205.452.86021 Boehringer Ingelheim Investigational Site	Chengdu
China	205.452.86032 Boehringer Ingelheim Investigational Site	Chengdu
China	205.452.86034 Boehringer Ingelheim Investigational Site	Chongqing
China	205.452.86035 Boehringer Ingelheim Investigational Site	Chongqing
China	205.452.86036 Boehringer Ingelheim Investigational Site	Chongqing
China	205.452.86020 Boehringer Ingelheim Investigational Site	Foshan
China	205.452.86001 Boehringer Ingelheim Investigational Site	Guangzhou
China	205.452.86004 Boehringer Ingelheim Investigational Site	Guangzhou
China	205.452.86005 Boehringer Ingelheim Investigational Site	Guangzhou
China	205.452.86019 Boehringer Ingelheim Investigational Site	Guangzhou
China	205.452.86028 Boehringer Ingelheim Investigational Site	Guangzhou
China	205.452.86030 Boehringer Ingelheim Investigational Site	Haikou
China	205.452.86007 Boehringer Ingelheim Investigational Site	Hangzhou
China	205.452.86008 Boehringer Ingelheim Investigational Site	Hangzhou
China	205.452.86029 Boehringer Ingelheim Investigational Site	Nan Ning
China	205.452.86037 Boehringer Ingelheim Investigational Site	Nanchang
China	205.452.86022 Boehringer Ingelheim Investigational Site	Nanjing
China	205.452.86027 Boehringer Ingelheim Investigational Site	Qingdao
China	205.452.86002 Boehringer Ingelheim Investigational Site	Shanghai
China	205.452.86003 Boehringer Ingelheim Investigational Site	Shanghai
China	205.452.86018 Boehringer Ingelheim Investigational Site	Shanghai
China	205.452.86014 Boehringer Ingelheim Investigational Site	Shenyang
China	205.452.86015 Boehringer Ingelheim Investigational Site	Shenyang
China	205.452.86006 Boehringer Ingelheim Investigational Site	Suzhou
China	205.452.86033 Boehringer Ingelheim Investigational Site	Tianjin
China	205.452.86031 Boehringer Ingelheim Investigational Site	Wuhan
China	205.452.86016 Boehringer Ingelheim Investigational Site	Xi'An
China	205.452.86017 Boehringer Ingelheim Investigational Site	Xi'An
Colombia	205.452.57002 Boehringer Ingelheim Investigational Site	Bogotá
Colombia	205.452.57004 Boehringer Ingelheim Investigational Site	Bogotá
Colombia	205.452.57005 Boehringer Ingelheim Investigational Site	Bogotá
Colombia	205.452.57006 Boehringer Ingelheim Investigational Site	Bogotá
Colombia	205.452.57001 Boehringer Ingelheim Investigational Site	Medellín
Croatia	205.452.38512 Boehringer Ingelheim Investigational Site	Cakovec
Croatia	205.452.38508 Boehringer Ingelheim Investigational Site	Dubrovnik
Croatia	205.452.38510 Boehringer Ingelheim Investigational Site	Osijek
Croatia	205.452.38501 Boehringer Ingelheim Investigational Site	Rijeka
Croatia	205.452.38506 Boehringer Ingelheim Investigational Site	Sisak
Croatia	205.452.38502 Boehringer Ingelheim Investigational Site	Split
Croatia	205.452.38503 Boehringer Ingelheim Investigational Site	Split
Croatia	205.452.38504 Boehringer Ingelheim Investigational Site	Zagreb
Croatia	205.452.38505 Boehringer Ingelheim Investigational Site	Zagreb
Croatia	205.452.38507 Boehringer Ingelheim Investigational Site	Zagreb
Croatia	205.452.38509 Boehringer Ingelheim Investigational Site	Zagreb
Croatia	205.452.38511 Boehringer Ingelheim Investigational Site	Zagreb
Denmark	205.452.45002 Boehringer Ingelheim Investigational Site	Aalborg
Denmark	205.452.45003 Boehringer Ingelheim Investigational Site	Aarhus C
Denmark	205.452.45006 Boehringer Ingelheim Investigational Site	Birkerød
Denmark	205.452.45001 Boehringer Ingelheim Investigational Site	København NV
Denmark	205.452.45005 Boehringer Ingelheim Investigational Site	København S
Denmark	205.452.45013 Boehringer Ingelheim Investigational Site	Kolding
Denmark	205.452.45012 Boehringer Ingelheim Investigational Site	Odense C
Denmark	205.452.45009 Boehringer Ingelheim Investigational Site	Rødovre
Denmark	205.452.45010 Boehringer Ingelheim Investigational Site	Rødovre
Denmark	205.452.45016 Boehringer Ingelheim Investigational Site	Roskilde
Denmark	205.452.45004 Boehringer Ingelheim Investigational Site	Silkeborg
Denmark	205.452.45014 Boehringer Ingelheim Investigational Site	Skive
Denmark	205.452.45011 Boehringer Ingelheim Investigational Site	Sønderborg
Denmark	205.452.45007 Boehringer Ingelheim Investigational Site	Værløse
Denmark	205.452.45015 Boehringer Ingelheim Investigational Site	Viby
Finland	205.452.35801 Boehringer Ingelheim Investigational Site	Helsinki
Finland	205.452.35804 Boehringer Ingelheim Investigational Site	Lahti
Finland	205.452.35808 Boehringer Ingelheim Investigational Site	Pori
Finland	205.452.35805 Boehringer Ingelheim Investigational Site	Porvoo
Finland	205.452.35806 Boehringer Ingelheim Investigational Site	Tammisaari
Finland	205.452.35802 Boehringer Ingelheim Investigational Site	Tampere
Finland	205.452.35803 Boehringer Ingelheim Investigational Site	Turku
France	205.452.33087 Boehringer Ingelheim Investigational Site	Albens
France	205.452.33028 Boehringer Ingelheim Investigational Site	Angers
France	205.452.33055 Boehringer Ingelheim Investigational Site	Angers
France	205.452.33142 Boehringer Ingelheim Investigational Site	Angers
France	205.452.33159 Boehringer Ingelheim Investigational Site	Angers
France	205.452.33030 Boehringer Ingelheim Investigational Site	Anzin
France	205.452.33158 Boehringer Ingelheim Investigational Site	Arras
France	205.452.33084 Boehringer Ingelheim Investigational Site	Avrillé
France	205.452.33128 Boehringer Ingelheim Investigational Site	Becon les Granits
France	205.452.33029 Boehringer Ingelheim Investigational Site	Bersée
France	205.452.33018 Boehringer Ingelheim Investigational Site	Beziers
France	205.452.33053 Boehringer Ingelheim Investigational Site	Bischheim
France	205.452.33024 Boehringer Ingelheim Investigational Site	Blois
France	205.452.33043 Boehringer Ingelheim Investigational Site	Bort les Orgues
France	205.452.33091 Boehringer Ingelheim Investigational Site	Bourg des cptes
France	205.452.33123 Boehringer Ingelheim Investigational Site	Briollay
France	205.452.33063 Boehringer Ingelheim Investigational Site	Broglie
France	205.452.33074 Boehringer Ingelheim Investigational Site	Bruay La Buissiere
France	205.452.33118 Boehringer Ingelheim Investigational Site	Cannes
France	205.452.33010 Boehringer Ingelheim Investigational Site	Cannes Cedex
France	205.452.33009 Boehringer Ingelheim Investigational Site	Chamalières
France	205.452.33073 Boehringer Ingelheim Investigational Site	Chambery
France	205.452.33059 Boehringer Ingelheim Investigational Site	Chateau Renault
France	205.452.33089 Boehringer Ingelheim Investigational Site	Colombey les Belles
France	205.452.33099 Boehringer Ingelheim Investigational Site	Cournonterral
France	205.452.33127 Boehringer Ingelheim Investigational Site	Cournonterral
France	205.452.33162 Boehringer Ingelheim Investigational Site	Croix
France	205.452.33105 Boehringer Ingelheim Investigational Site	Dinard
France	205.452.33110 Boehringer Ingelheim Investigational Site	Donges
France	205.452.33094 Boehringer Ingelheim Investigational Site	Gambsheim
France	205.452.33046 Boehringer Ingelheim Investigational Site	Grenoble
France	205.452.33096 Boehringer Ingelheim Investigational Site	Hautmont
France	205.452.33090 Boehringer Ingelheim Investigational Site	Hinx
France	205.452.33145 Boehringer Ingelheim Investigational Site	Jarny
France	205.452.33154 Boehringer Ingelheim Investigational Site	La Bouëxière
France	205.452.33065 Boehringer Ingelheim Investigational Site	La Chapelle sur Erdre
France	205.452.33102 Boehringer Ingelheim Investigational Site	La Montagne
France	205.452.33100 Boehringer Ingelheim Investigational Site	La Riche
France	205.452.33058 Boehringer Ingelheim Investigational Site	Lambersart
France	205.452.33098 Boehringer Ingelheim Investigational Site	Lambersart
France	205.452.33103 Boehringer Ingelheim Investigational Site	Levallois Perret
France	205.452.33164 Boehringer Ingelheim Investigational Site	Louvigne De bais
France	205.452.33111 Boehringer Ingelheim Investigational Site	Luynes
France	205.452.33136 Boehringer Ingelheim Investigational Site	Marcq en Baroeul
France	205.452.33115 Boehringer Ingelheim Investigational Site	Mondelange
France	205.452.33088 Boehringer Ingelheim Investigational Site	Mont de Marsan
France	205.452.33138 Boehringer Ingelheim Investigational Site	Mont de Marsan
France	205.452.33005 Boehringer Ingelheim Investigational Site	Montigny les Metz
France	205.452.33163 Boehringer Ingelheim Investigational Site	Mundolsheim
France	205.452.33109 Boehringer Ingelheim Investigational Site	Murs Erigne
France	205.452.33031 Boehringer Ingelheim Investigational Site	Nantes
France	205.452.33003 Boehringer Ingelheim Investigational Site	Nice
France	205.452.33108 Boehringer Ingelheim Investigational Site	Oignies
France	205.452.33014 Boehringer Ingelheim Investigational Site	Ollioules
France	205.452.33157 Boehringer Ingelheim Investigational Site	Orthez
France	205.452.33112 Boehringer Ingelheim Investigational Site	Parcay les Pins
France	205.452.33001 Boehringer Ingelheim Investigational Site	Paris
France	205.452.33051 Boehringer Ingelheim Investigational Site	Paris
France	205.452.33082 Boehringer Ingelheim Investigational Site	Paris
France	205.452.33165 Boehringer Ingelheim Investigational Site	Paris
France	205.452.33130 Boehringer Ingelheim Investigational Site	Pont à Mousson
France	205.452.33122 Boehringer Ingelheim Investigational Site	Quarouble
France	205.452.33006 Boehringer Ingelheim Investigational Site	Reims
France	205.452.33153 Boehringer Ingelheim Investigational Site	Rosiers d'Egletons
France	205.452.33161 Boehringer Ingelheim Investigational Site	Rugles
France	205.452.33126 Boehringer Ingelheim Investigational Site	Saint Alban Leysse
France	205.452.33140 Boehringer Ingelheim Investigational Site	Saint Aulaire
France	205.452.33052 Boehringer Ingelheim Investigational Site	Saint Avertin
France	205.452.33011 Boehringer Ingelheim Investigational Site	Saint Léger des Bois
France	205.452.33002 Boehringer Ingelheim Investigational Site	Saintes
France	205.452.33148 Boehringer Ingelheim Investigational Site	Salies de Bearn
France	205.452.33026 Boehringer Ingelheim Investigational Site	Savonnières
France	205.452.33067 Boehringer Ingelheim Investigational Site	Segre
France	205.452.33040 Boehringer Ingelheim Investigational Site	Serres Casset
France	205.452.33012 Boehringer Ingelheim Investigational Site	Six Four les Plages
France	205.452.33160 Boehringer Ingelheim Investigational Site	St Jouan des Guerets
France	205.452.33079 Boehringer Ingelheim Investigational Site	St Sebastien sur Loire
France	205.452.33007 Boehringer Ingelheim Investigational Site	Strasbourg
France	205.452.33033 Boehringer Ingelheim Investigational Site	Strasbourg
France	205.452.33097 Boehringer Ingelheim Investigational Site	Strasbourg
France	205.452.33101 Boehringer Ingelheim Investigational Site	Strasbourg
France	205.452.33107 Boehringer Ingelheim Investigational Site	Thouars
France	205.452.33116 Boehringer Ingelheim Investigational Site	Tinténiac
France	205.452.33013 Boehringer Ingelheim Investigational Site	Toulon
France	205.452.33054 Boehringer Ingelheim Investigational Site	Tours
France	205.452.33064 Boehringer Ingelheim Investigational Site	Tours
France	205.452.33092 Boehringer Ingelheim Investigational Site	Tours
France	205.452.33124 Boehringer Ingelheim Investigational Site	Tours
France	205.452.33066 Boehringer Ingelheim Investigational Site	Vendôme
France	205.452.33137 Boehringer Ingelheim Investigational Site	Vernoil
France	205.452.33032 Boehringer Ingelheim Investigational Site	Vieux Condé
France	205.452.33151 Boehringer Ingelheim Investigational Site	Vihiers
France	205.452.33077 Boehringer Ingelheim Investigational Site	Villey St Etienne
France	205.452.33135 Boehringer Ingelheim Investigational Site	Wattrelos
Georgia	205.452.99501 Boehringer Ingelheim Investigational Site	Tbilisi
Georgia	205.452.99502 Boehringer Ingelheim Investigational Site	Tbilisi
Georgia	205.452.99503 Boehringer Ingelheim Investigational Site	Tbilisi
Georgia	205.452.99504 Boehringer Ingelheim Investigational Site	Tbilisi
Georgia	205.452.99505 Boehringer Ingelheim Investigational Site	Tbilisi
Georgia	205.452.99506 Boehringer Ingelheim Investigational Site	Tbilisi
Georgia	205.452.99507 Boehringer Ingelheim Investigational Site	Tbilisi
Germany	205.452.49096 Boehringer Ingelheim Investigational Site	Aschaffenburg
Germany	205.452.49130 Boehringer Ingelheim Investigational Site	Augsburg
Germany	205.452.49161 Boehringer Ingelheim Investigational Site	Augsburg
Germany	205.452.49001 Boehringer Ingelheim Investigational Site	Backnang
Germany	205.452.49173 Boehringer Ingelheim Investigational Site	Bad Kissingen
Germany	205.452.49134 Boehringer Ingelheim Investigational Site	Bad Lippspringe
Germany	205.452.49082 Boehringer Ingelheim Investigational Site	Bad Neustadt
Germany	205.452.49058 Boehringer Ingelheim Investigational Site	Bad Wörishofen
Germany	205.452.49145 Boehringer Ingelheim Investigational Site	Bamberg
Germany	205.452.49072 Boehringer Ingelheim Investigational Site	Bensheim
Germany	205.452.49048 Boehringer Ingelheim Investigational Site	Bergisch Gladbach
Germany	205.452.49006 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49016 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49028 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49031 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49054 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49064 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49066 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49068 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49102 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49135 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49138 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49157 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49167 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49175 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49180 Boehringer Ingelheim Investigational Site	Berlin
Germany	205.452.49037 Boehringer Ingelheim Investigational Site	Bonn
Germany	205.452.49118 Boehringer Ingelheim Investigational Site	Bonn
Germany	205.452.49083 Boehringer Ingelheim Investigational Site	Brake
Germany	205.452.49040 Boehringer Ingelheim Investigational Site	Bruchsal
Germany	205.452.49089 Boehringer Ingelheim Investigational Site	Celle
Germany	205.452.49143 Boehringer Ingelheim Investigational Site	Cottbus
Germany	205.452.49119 Boehringer Ingelheim Investigational Site	Deggendorf
Germany	205.452.49151 Boehringer Ingelheim Investigational Site	Dillingen
Germany	205.452.49117 Boehringer Ingelheim Investigational Site	Donaueschingen
Germany	205.452.49015 Boehringer Ingelheim Investigational Site	Dortmund
Germany	205.452.49008 Boehringer Ingelheim Investigational Site	Düren
Germany	205.452.49098 Boehringer Ingelheim Investigational Site	Emden
Germany	205.452.49003 Boehringer Ingelheim Investigational Site	Engelskirchen
Germany	205.452.49024 Boehringer Ingelheim Investigational Site	Ense
Germany	205.452.49168 Boehringer Ingelheim Investigational Site	Essen
Germany	205.452.49133 Boehringer Ingelheim Investigational Site	Föhren
Germany	205.452.49104 Boehringer Ingelheim Investigational Site	Forchheim
Germany	205.452.49070 Boehringer Ingelheim Investigational Site	Frankfurt
Germany	205.452.49147 Boehringer Ingelheim Investigational Site	Frankfurt
Germany	205.452.49137 Boehringer Ingelheim Investigational Site	Fulda
Germany	205.452.49107 Boehringer Ingelheim Investigational Site	Gelnhausen
Germany	205.452.49032 Boehringer Ingelheim Investigational Site	Gütersloh
Germany	205.452.49026 Boehringer Ingelheim Investigational Site	Hagen
Germany	205.452.49041 Boehringer Ingelheim Investigational Site	Hagen
Germany	205.452.49044 Boehringer Ingelheim Investigational Site	Hamburg
Germany	205.452.49061 Boehringer Ingelheim Investigational Site	Hamburg
Germany	205.452.49080 Boehringer Ingelheim Investigational Site	Hamburg
Germany	205.452.49038 Boehringer Ingelheim Investigational Site	Hannover
Germany	205.452.49052 Boehringer Ingelheim Investigational Site	Hannover
Germany	205.452.49094 Boehringer Ingelheim Investigational Site	Hannover
Germany	205.452.49181 Boehringer Ingelheim Investigational Site	Heidelberg
Germany	205.452.49116 Boehringer Ingelheim Investigational Site	Heilbronn
Germany	205.452.49022 Boehringer Ingelheim Investigational Site	Hemmingen
Germany	205.452.49007 Boehringer Ingelheim Investigational Site	Höchstädt
Germany	205.452.49136 Boehringer Ingelheim Investigational Site	Ingelheim
Germany	205.452.49047 Boehringer Ingelheim Investigational Site	Käbschütztal-Krögis
Germany	205.452.49159 Boehringer Ingelheim Investigational Site	Karlsruhe
Germany	205.452.49027 Boehringer Ingelheim Investigational Site	Kassel
Germany	205.452.49105 Boehringer Ingelheim Investigational Site	Kaufbeuren
Germany	205.452.49101 Boehringer Ingelheim Investigational Site	Koblenz
Germany	205.452.49146 Boehringer Ingelheim Investigational Site	Köln
Germany	205.452.49114 Boehringer Ingelheim Investigational Site	Landsberg am Lech
Germany	205.452.49169 Boehringer Ingelheim Investigational Site	Langen
Germany	205.452.49017 Boehringer Ingelheim Investigational Site	Leipzig
Germany	205.452.49035 Boehringer Ingelheim Investigational Site	Leipzig
Germany	205.452.49113 Boehringer Ingelheim Investigational Site	Leipzig
Germany	205.452.49139 Boehringer Ingelheim Investigational Site	Leipzig
Germany	205.452.49172 Boehringer Ingelheim Investigational Site	Leipzig
Germany	205.452.49110 Boehringer Ingelheim Investigational Site	Leonberg
Germany	205.452.49088 Boehringer Ingelheim Investigational Site	Mannheim
Germany	205.452.49108 Boehringer Ingelheim Investigational Site	Marburg
Germany	205.452.49122 Boehringer Ingelheim Investigational Site	Marburg
Germany	205.452.49055 Boehringer Ingelheim Investigational Site	Minden
Germany	205.452.49025 Boehringer Ingelheim Investigational Site	München
Germany	205.452.49131 Boehringer Ingelheim Investigational Site	München
Germany	205.452.49023 Boehringer Ingelheim Investigational Site	Neumünster
Germany	205.452.49132 Boehringer Ingelheim Investigational Site	Neuruppin
Germany	205.452.49045 Boehringer Ingelheim Investigational Site	Neuwied
Germany	205.452.49062 Boehringer Ingelheim Investigational Site	Oranienburg
Germany	205.452.49124 Boehringer Ingelheim Investigational Site	Oschersleben
Germany	205.452.49019 Boehringer Ingelheim Investigational Site	Paderborn
Germany	205.452.49053 Boehringer Ingelheim Investigational Site	Potsdam
Germany	205.452.49076 Boehringer Ingelheim Investigational Site	Potsdam
Germany	205.452.49049 Boehringer Ingelheim Investigational Site	Radebeul
Germany	205.452.49056 Boehringer Ingelheim Investigational Site	Rathenow
Germany	205.452.49009 Boehringer Ingelheim Investigational Site	Raubach
Germany	205.452.49002 Boehringer Ingelheim Investigational Site	Rehau
Germany	205.452.49142 Boehringer Ingelheim Investigational Site	Reinfeld
Germany	205.452.49030 Boehringer Ingelheim Investigational Site	Rhaunen
Germany	205.452.49184 Boehringer Ingelheim Investigational Site	Rheine
Germany	205.452.49077 Boehringer Ingelheim Investigational Site	Rodgau-Dudenhofen
Germany	205.452.49021 Boehringer Ingelheim Investigational Site	Rüsselsheim
Germany	205.452.49091 Boehringer Ingelheim Investigational Site	Rüsselsheim
Germany	205.452.49042 Boehringer Ingelheim Investigational Site	Saarlouis
Germany	205.452.49034 Boehringer Ingelheim Investigational Site	Schwetzingen
Germany	205.452.49013 Boehringer Ingelheim Investigational Site	Solingen
Germany	205.452.49057 Boehringer Ingelheim Investigational Site	Solingen
Germany	205.452.49078 Boehringer Ingelheim Investigational Site	Tübingen
Germany	205.452.49099 Boehringer Ingelheim Investigational Site	Ulm
Germany	205.452.49043 Boehringer Ingelheim Investigational Site	Wallerfing
Germany	205.452.49067 Boehringer Ingelheim Investigational Site	Wardenburg
Germany	205.452.49165 Boehringer Ingelheim Investigational Site	Warendorf
Germany	205.452.49051 Boehringer Ingelheim Investigational Site	Weinheim
Germany	205.452.49127 Boehringer Ingelheim Investigational Site	Weyhe
Germany	205.452.49092 Boehringer Ingelheim Investigational Site	Wiesloch
Germany	205.452.49018 Boehringer Ingelheim Investigational Site	Witten
Germany	205.452.49029 Boehringer Ingelheim Investigational Site	Witten
Germany	205.452.49095 Boehringer Ingelheim Investigational Site	Wolfsburg
Germany	205.452.49060 Boehringer Ingelheim Investigational Site	Zerbst
Greece	205.452.30002 Boehringer Ingelheim Investigational Site	Athens
Greece	205.452.30003 Boehringer Ingelheim Investigational Site	Athens
Greece	205.452.30008 Boehringer Ingelheim Investigational Site	Athens
Greece	205.452.30001 Boehringer Ingelheim Investigational Site	Heraklion
Greece	205.452.30007 Boehringer Ingelheim Investigational Site	Kalamaria
Greece	205.452.30010 Boehringer Ingelheim Investigational Site	Kavala
Greece	205.452.30012 Boehringer Ingelheim Investigational Site	Lamia
Greece	205.452.30005 Boehringer Ingelheim Investigational Site	Nafplio
Greece	205.452.30011 Boehringer Ingelheim Investigational Site	Rethymno
Greece	205.452.30006 Boehringer Ingelheim Investigational Site	Serres
Greece	205.452.30004 Boehringer Ingelheim Investigational Site	Thessaloniki
Greece	205.452.30009 Boehringer Ingelheim Investigational Site	Thessaloniki
Guatemala	205.452.50205 Boehringer Ingelheim Investigational Site	Guatemala
Guatemala	205.452.50206 Boehringer Ingelheim Investigational Site	Guatemala
Guatemala	205.452.50203 Boehringer Ingelheim Investigational Site	Nivel 12
Guatemala	205.452.50201 Boehringer Ingelheim Investigational Site	Nivel Guatemala
Guatemala	205.452.50202 Boehringer Ingelheim Investigational Site	Nivel Guatemala
Guatemala	205.452.50204 Boehringer Ingelheim Investigational Site	Nivel Guatemala
Guatemala	205.452.50207 Boehringer Ingelheim Investigational Site	Quetzaltenango
Hungary	205.452.36005 Boehringer Ingelheim Investigational Site	Baja
Hungary	205.452.36004 Boehringer Ingelheim Investigational Site	Budapest
Hungary	205.452.36016 Boehringer Ingelheim Investigational Site	Budapest
Hungary	205.452.36030 Boehringer Ingelheim Investigational Site	Budapest
Hungary	205.452.36007 Boehringer Ingelheim Investigational Site	Debrecen
Hungary	205.452.36013 Boehringer Ingelheim Investigational Site	Debrecen
Hungary	205.452.36015 Boehringer Ingelheim Investigational Site	Debrecen
Hungary	205.452.36029 Boehringer Ingelheim Investigational Site	Deszk
Hungary	205.452.36026 Boehringer Ingelheim Investigational Site	Dombovar
Hungary	205.452.36003 Boehringer Ingelheim Investigational Site	Erd
Hungary	205.452.36008 Boehringer Ingelheim Investigational Site	Farkasgyepü
Hungary	205.452.36020 Boehringer Ingelheim Investigational Site	Györ
Hungary	205.452.36012 Boehringer Ingelheim Investigational Site	Hajduböszörmeny
Hungary	205.452.36023 Boehringer Ingelheim Investigational Site	Hodmezovasarhely
Hungary	205.452.36010 Boehringer Ingelheim Investigational Site	Kaposvar
Hungary	205.452.36018 Boehringer Ingelheim Investigational Site	Kapuvar
Hungary	205.452.36002 Boehringer Ingelheim Investigational Site	Kecskemet
Hungary	205.452.36001 Boehringer Ingelheim Investigational Site	Makó
Hungary	205.452.36006 Boehringer Ingelheim Investigational Site	Mohacs
Hungary	205.452.36022 Boehringer Ingelheim Investigational Site	Mosonmagyarovar
Hungary	205.452.36027 Boehringer Ingelheim Investigational Site	Nagykanizsa
Hungary	205.452.36014 Boehringer Ingelheim Investigational Site	Nyiregyhaza
Hungary	205.452.36009 Boehringer Ingelheim Investigational Site	Pecs
Hungary	205.452.36011 Boehringer Ingelheim Investigational Site	Pecs
Hungary	205.452.36028 Boehringer Ingelheim Investigational Site	Siófok
Hungary	205.452.36021 Boehringer Ingelheim Investigational Site	Szarvas
Hungary	205.452.36017 Boehringer Ingelheim Investigational Site	Szeged
Hungary	205.452.36024 Boehringer Ingelheim Investigational Site	Tatabanya
Hungary	205.452.36019 Boehringer Ingelheim Investigational Site	Törökbálint
Hungary	205.452.36025 Boehringer Ingelheim Investigational Site	Törökbálint
India	205.452.91017 Boehringer Ingelheim Investigational Site	Ahmedabad
India	205.452.91018 Boehringer Ingelheim Investigational Site	Chennai
India	205.452.91001 Boehringer Ingelheim Investigational Site	Coimbatore
India	205.452.91002 Boehringer Ingelheim Investigational Site	Coimbatore
India	205.452.91014 Boehringer Ingelheim Investigational Site	Dadar(East)
India	205.452.91005 Boehringer Ingelheim Investigational Site	Hyderabad
India	205.452.91009 Boehringer Ingelheim Investigational Site	Hyderabad
India	205.452.91004 Boehringer Ingelheim Investigational Site	Jaipur
India	205.452.91007 Boehringer Ingelheim Investigational Site	Jaipur
India	205.452.91015 Boehringer Ingelheim Investigational Site	Jaipur
India	205.452.91016 Boehringer Ingelheim Investigational Site	Jaipur
India	205.452.91008 Boehringer Ingelheim Investigational Site	Karnataka
India	205.452.91006 Boehringer Ingelheim Investigational Site	Maharashtra
India	205.452.91003 Boehringer Ingelheim Investigational Site	Maharastra
India	205.452.91011 Boehringer Ingelheim Investigational Site	Punjab
Ireland	205.452.35307 Boehringer Ingelheim Investigational Site	Co. Cork
Ireland	205.452.35306 Boehringer Ingelheim Investigational Site	Co. Tipperary
Ireland	205.452.35305 Boehringer Ingelheim Investigational Site	Co. Wexford
Ireland	205.452.35302 Boehringer Ingelheim Investigational Site	Dublin
Ireland	205.452.35301 Boehringer Ingelheim Investigational Site	Dublin 24
Ireland	205.452.35303 Boehringer Ingelheim Investigational Site	Limerick
Ireland	205.452.35308 Boehringer Ingelheim Investigational Site	Limerick
Ireland	205.452.35304 Boehringer Ingelheim Investigational Site	Offaly
Israel	205.452.97207 Boehringer Ingelheim Investigational Site	Ashkelon
Israel	205.452.97204 Boehringer Ingelheim Investigational Site	Beer Sheva
Israel	205.452.97208 Boehringer Ingelheim Investigational Site	Haifa
Israel	205.452.97202 Boehringer Ingelheim Investigational Site	Jerusalem
Israel	205.452.97206 Boehringer Ingelheim Investigational Site	Kfar Saba
Israel	205.452.97203 Boehringer Ingelheim Investigational Site	Petach Tikva
Israel	205.452.97201 Boehringer Ingelheim Investigational Site	Rehovot
Israel	205.452.97205 Boehringer Ingelheim Investigational Site	Tel-Aviv
Italy	205.452.39003 Boehringer Ingelheim Investigational Site	Arenzano (ge)
Italy	205.452.39019 Boehringer Ingelheim Investigational Site	Ascoli Piceno
Italy	205.452.39016 Boehringer Ingelheim Investigational Site	Avellino
Italy	205.452.39007 Boehringer Ingelheim Investigational Site	Benevento
Italy	205.452.39024 Boehringer Ingelheim Investigational Site	Brescia
Italy	205.452.39029 Boehringer Ingelheim Investigational Site	Busto Arsizio (va)
Italy	205.452.39011 Boehringer Ingelheim Investigational Site	Cagliari
Italy	205.452.39013 Boehringer Ingelheim Investigational Site	Cagliari
Italy	205.452.39020 Boehringer Ingelheim Investigational Site	Cagliari
Italy	205.452.39015 Boehringer Ingelheim Investigational Site	Catanzaro
Italy	205.452.39006 Boehringer Ingelheim Investigational Site	Chieti Scalo
Italy	205.452.39001 Boehringer Ingelheim Investigational Site	Firenze
Italy	205.452.39021 Boehringer Ingelheim Investigational Site	Monza
Italy	205.452.39014 Boehringer Ingelheim Investigational Site	Napoli
Italy	205.452.39012 Boehringer Ingelheim Investigational Site	Orbassano (to)
Italy	205.452.39026 Boehringer Ingelheim Investigational Site	Orbassano (to)
Italy	205.452.39010 Boehringer Ingelheim Investigational Site	Palermo
Italy	205.452.39005 Boehringer Ingelheim Investigational Site	Parma
Italy	205.452.39009 Boehringer Ingelheim Investigational Site	Perugia
Italy	205.452.39002 Boehringer Ingelheim Investigational Site	Prato
Italy	205.452.39030 Boehringer Ingelheim Investigational Site	Reggio Emilia
Italy	205.452.39004 Boehringer Ingelheim Investigational Site	Roma
Italy	205.452.39017 Boehringer Ingelheim Investigational Site	Roma
Italy	205.452.39027 Boehringer Ingelheim Investigational Site	Roma
Italy	205.452.39023 Boehringer Ingelheim Investigational Site	Treviso
Korea, Republic of	205.452.82008 Boehringer Ingelheim Investigational Site	Bucheon
Korea, Republic of	205.452.82002 Boehringer Ingelheim Investigational Site	Busan
Korea, Republic of	205.452.82012 Boehringer Ingelheim Investigational Site	Busan
Korea, Republic of	205.452.82010 Boehringer Ingelheim Investigational Site	Daegu
Korea, Republic of	205.452.82016 Boehringer Ingelheim Investigational Site	Daejoen
Korea, Republic of	205.452.82009 Boehringer Ingelheim Investigational Site	Gangwon-Do
Korea, Republic of	205.452.82017 Boehringer Ingelheim Investigational Site	Goyang
Korea, Republic of	205.452.82004 Boehringer Ingelheim Investigational Site	Gwangju
Korea, Republic of	205.452.82005 Boehringer Ingelheim Investigational Site	Incheon
Korea, Republic of	205.452.82020 Boehringer Ingelheim Investigational Site	Jeonju
Korea, Republic of	205.452.82001 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	205.452.82003 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	205.452.82006 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	205.452.82007 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	205.452.82011 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	205.452.82013 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	205.452.82014 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	205.452.82015 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	205.452.82018 Boehringer Ingelheim Investigational Site	Seoul
Korea, Republic of	205.452.82019 Boehringer Ingelheim Investigational Site	Uijeongbu
Latvia	205.452.37106 Boehringer Ingelheim Investigational Site	Daugavpils
Latvia	205.452.37107 Boehringer Ingelheim Investigational Site	Daugavpils
Latvia	205.452.37108 Boehringer Ingelheim Investigational Site	Daugavpils
Latvia	205.452.37102 Boehringer Ingelheim Investigational Site	Kraslava
Latvia	205.452.37104 Boehringer Ingelheim Investigational Site	Riga
Latvia	205.452.37105 Boehringer Ingelheim Investigational Site	Riga
Latvia	205.452.37109 Boehringer Ingelheim Investigational Site	Riga
Latvia	205.452.37110 Boehringer Ingelheim Investigational Site	Riga
Latvia	205.452.37101 Boehringer Ingelheim Investigational Site	Talsi
Latvia	205.452.37103 Boehringer Ingelheim Investigational Site	Valmiera
Lithuania	205.452.37003 Boehringer Ingelheim Investigational Site	Alytus
Lithuania	205.452.37001 Boehringer Ingelheim Investigational Site	Kaunas
Lithuania	205.452.37002 Boehringer Ingelheim Investigational Site	Kaunas
Lithuania	205.452.37005 Boehringer Ingelheim Investigational Site	Klaipeda
Lithuania	205.452.37007 Boehringer Ingelheim Investigational Site	Siauliai
Lithuania	205.452.37011 Boehringer Ingelheim Investigational Site	Utena
Lithuania	205.452.37004 Boehringer Ingelheim Investigational Site	Vilnius
Lithuania	205.452.37008 Boehringer Ingelheim Investigational Site	Vilnius
Lithuania	205.452.37010 Boehringer Ingelheim Investigational Site	Vilnius
Malaysia	205.452.60006 Boehringer Ingelheim Investigational Site	Johor Bahru
Malaysia	205.452.60001 Boehringer Ingelheim Investigational Site	Kuala Lumpur
Malaysia	205.452.60002 Boehringer Ingelheim Investigational Site	Kuala Lumpur
Malaysia	205.452.60004 Boehringer Ingelheim Investigational Site	Kuala Lumpur
Malaysia	205.452.60008 Boehringer Ingelheim Investigational Site	Pahang
Malaysia	205.452.60005 Boehringer Ingelheim Investigational Site	Sarawak
Malaysia	205.452.60009 Boehringer Ingelheim Investigational Site	Selangor
Malaysia	205.452.60007 Boehringer Ingelheim Investigational Site	Terengganu
Mexico	205.452.52004 Boehringer Ingelheim Investigational Site	Aguascalientes
Mexico	205.452.52007 Boehringer Ingelheim Investigational Site	Distrito Federal
Mexico	205.452.52005 Boehringer Ingelheim Investigational Site	Guadalajara
Mexico	205.452.52001 Boehringer Ingelheim Investigational Site	México
Mexico	205.452.52002 Boehringer Ingelheim Investigational Site	Monte Rey
Mexico	205.452.52003 Boehringer Ingelheim Investigational Site	Zona Río
Netherlands	205.452.31001 Boehringer Ingelheim Investigational Site	Almere
Netherlands	205.452.31008 Boehringer Ingelheim Investigational Site	Andijk
Netherlands	205.452.31002 Boehringer Ingelheim Investigational Site	Beek
Netherlands	205.452.31012 Boehringer Ingelheim Investigational Site	Beek En Donk
Netherlands	205.452.31003 Boehringer Ingelheim Investigational Site	Ermelo
Netherlands	205.452.31010 Boehringer Ingelheim Investigational Site	Hoogwoud
Netherlands	205.452.31011 Boehringer Ingelheim Investigational Site	Nijverdal
Netherlands	205.452.31007 Boehringer Ingelheim Investigational Site	Oude Pekela
Netherlands	205.452.31005 Boehringer Ingelheim Investigational Site	Roelofarendsveen
New Zealand	205.452.64004 Boehringer Ingelheim Investigational Site	Christchurch
New Zealand	205.452.64003 Boehringer Ingelheim Investigational Site	Dunedin
New Zealand	205.452.64002 Boehringer Ingelheim Investigational Site	Newtown Wellington NZ
New Zealand	205.452.64001 Boehringer Ingelheim Investigational Site	Tauranga
Norway	205.452.47008 Boehringer Ingelheim Investigational Site	Drammen
Norway	205.452.47009 Boehringer Ingelheim Investigational Site	Fredrikstad
Norway	205.452.47001 Boehringer Ingelheim Investigational Site	Hønefoss
Norway	205.452.47010 Boehringer Ingelheim Investigational Site	Kløfta
Norway	205.452.47007 Boehringer Ingelheim Investigational Site	Kolbjørnsvik
Norway	205.452.47005 Boehringer Ingelheim Investigational Site	Løvenstad
Norway	205.452.47002 Boehringer Ingelheim Investigational Site	Oslo
Norway	205.452.47003 Boehringer Ingelheim Investigational Site	Oslo
Norway	205.452.47011 Boehringer Ingelheim Investigational Site	Oslo
Norway	205.452.47012 Boehringer Ingelheim Investigational Site	Sandvika
Norway	205.452.47004 Boehringer Ingelheim Investigational Site	Svelvik
Norway	205.452.47006 Boehringer Ingelheim Investigational Site	Trollåsen
Panama	205.452.50703 Boehringer Ingelheim Investigational Site	Carrasquilla
Panama	205.452.50701 Boehringer Ingelheim Investigational Site	Marbella
Panama	205.452.50702 Boehringer Ingelheim Investigational Site	Marbella
Peru	205.452.51002 Boehringer Ingelheim Investigational Site	Bellavista
Peru	205.452.51003 Boehringer Ingelheim Investigational Site	Cusco
Peru	205.452.51004 Boehringer Ingelheim Investigational Site	Jesús Maria
Peru	205.452.51007 Boehringer Ingelheim Investigational Site	Jesús María
Peru	205.452.51005 Boehringer Ingelheim Investigational Site	Lima
Peru	205.452.51001 Boehringer Ingelheim Investigational Site	San Isidro
Peru	205.452.51006 Boehringer Ingelheim Investigational Site	San Martin de Porres
Philippines	205.452.63004 Boehringer Ingelheim Investigational Site	Cavite City
Philippines	205.452.63002 Boehringer Ingelheim Investigational Site	Davao City
Philippines	205.452.63003 Boehringer Ingelheim Investigational Site	Iloilo City
Philippines	205.452.63006 Boehringer Ingelheim Investigational Site	Iloilo City
Philippines	205.452.63001 Boehringer Ingelheim Investigational Site	Manila
Philippines	205.452.63008 Boehringer Ingelheim Investigational Site	Manila
Philippines	205.452.63005 Boehringer Ingelheim Investigational Site	Quezon City
Philippines	205.452.63007 Boehringer Ingelheim Investigational Site	Quezon City
Poland	205.452.48031 Boehringer Ingelheim Investigational Site	Babice
Poland	205.452.48003 Boehringer Ingelheim Investigational Site	Bialystok
Poland	205.452.48011 Boehringer Ingelheim Investigational Site	Bialystok
Poland	205.452.48014 Boehringer Ingelheim Investigational Site	Bydgoszcz
Poland	205.452.48008 Boehringer Ingelheim Investigational Site	Checiny
Poland	205.452.48016 Boehringer Ingelheim Investigational Site	Gdansk
Poland	205.452.48019 Boehringer Ingelheim Investigational Site	Gdynia
Poland	205.452.48037 Boehringer Ingelheim Investigational Site	Gorzow Wlkp
Poland	205.452.48015 Boehringer Ingelheim Investigational Site	Ilawa
Poland	205.452.48033 Boehringer Ingelheim Investigational Site	Katowice
Poland	205.452.48039 Boehringer Ingelheim Investigational Site	Katowice
Poland	205.452.48044 Boehringer Ingelheim Investigational Site	Katowice
Poland	205.452.48009 Boehringer Ingelheim Investigational Site	Krakow
Poland	205.452.48021 Boehringer Ingelheim Investigational Site	Krakow
Poland	205.452.48029 Boehringer Ingelheim Investigational Site	Krakow
Poland	205.452.48030 Boehringer Ingelheim Investigational Site	Krakow
Poland	205.452.48048 Boehringer Ingelheim Investigational Site	Krakow
Poland	205.452.48043 Boehringer Ingelheim Investigational Site	Libiaz
Poland	205.452.48002 Boehringer Ingelheim Investigational Site	Lodz
Poland	205.452.48051 Boehringer Ingelheim Investigational Site	Lodz
Poland	205.452.48056 Boehringer Ingelheim Investigational Site	Lodz
Poland	205.452.48059 Boehringer Ingelheim Investigational Site	Lodz
Poland	205.452.48018 Boehringer Ingelheim Investigational Site	Olsztyn
Poland	205.452.48025 Boehringer Ingelheim Investigational Site	Ostrow Wielkopolska
Poland	205.452.48012 Boehringer Ingelheim Investigational Site	Piaseczno
Poland	205.452.48040 Boehringer Ingelheim Investigational Site	Piaseczno
Poland	205.452.48026 Boehringer Ingelheim Investigational Site	Poznan
Poland	205.452.48027 Boehringer Ingelheim Investigational Site	Poznan
Poland	205.452.48058 Boehringer Ingelheim Investigational Site	Poznan
Poland	205.452.48060 Boehringer Ingelheim Investigational Site	Rokietnica
Poland	205.452.48001 Boehringer Ingelheim Investigational Site	Skierniewice
Poland	205.452.48032 Boehringer Ingelheim Investigational Site	Slawkow
Poland	205.452.48036 Boehringer Ingelheim Investigational Site	Szczecin
Poland	205.452.48045 Boehringer Ingelheim Investigational Site	Tarnow
Poland	205.452.48057 Boehringer Ingelheim Investigational Site	Tczew
Poland	205.452.48004 Boehringer Ingelheim Investigational Site	Torun
Poland	205.452.48007 Boehringer Ingelheim Investigational Site	Tranow
Poland	205.452.48053 Boehringer Ingelheim Investigational Site	Turek
Poland	205.452.48034 Boehringer Ingelheim Investigational Site	Warsaw
Poland	205.452.48042 Boehringer Ingelheim Investigational Site	Warszawa
Poland	205.452.48049 Boehringer Ingelheim Investigational Site	Warszawa
Poland	205.452.48017 Boehringer Ingelheim Investigational Site	Wolomin
Poland	205.452.48006 Boehringer Ingelheim Investigational Site	Wroclaw
Poland	205.452.48028 Boehringer Ingelheim Investigational Site	Wroclaw
Poland	205.452.48035 Boehringer Ingelheim Investigational Site	Wroclaw
Poland	205.452.48038 Boehringer Ingelheim Investigational Site	Wroclaw
Poland	205.452.48022 Boehringer Ingelheim Investigational Site	Zakopane
Portugal	205.452.35103 Boehringer Ingelheim Investigational Site	Amadora
Portugal	205.452.35102 Boehringer Ingelheim Investigational Site	Coimbra
Portugal	205.452.35107 Boehringer Ingelheim Investigational Site	Lisboa
Portugal	205.452.35108 Boehringer Ingelheim Investigational Site	Lisboa
Portugal	205.452.35101 Boehringer Ingelheim Investigational Site	Matosinhos
Portugal	205.452.35105 Boehringer Ingelheim Investigational Site	Penafiel
Portugal	205.452.35106 Boehringer Ingelheim Investigational Site	Vila Nova de Gaia
Portugal	205.452.35104 Boehringer Ingelheim Investigational Site	Viseu
Puerto Rico	205.452.01177 Boehringer Ingelheim Investigational Site	Ponce
Puerto Rico	205.452.01162 Boehringer Ingelheim Investigational Site	San Juan
Romania	205.452.40008 Boehringer Ingelheim Investigational Site	Brasov
Romania	205.452.40012 Boehringer Ingelheim Investigational Site	Brasov
Romania	205.452.40001 Boehringer Ingelheim Investigational Site	Bucharest
Romania	205.452.40003 Boehringer Ingelheim Investigational Site	Bucharest
Romania	205.452.40004 Boehringer Ingelheim Investigational Site	Bucharest
Romania	205.452.40007 Boehringer Ingelheim Investigational Site	Bucharest
Romania	205.452.40009 Boehringer Ingelheim Investigational Site	Bucharest
Romania	205.452.40013 Boehringer Ingelheim Investigational Site	Bucharest
Romania	205.452.40002 Boehringer Ingelheim Investigational Site	Bucuresti
Romania	205.452.40011 Boehringer Ingelheim Investigational Site	Constanta
Romania	205.452.40006 Boehringer Ingelheim Investigational Site	Craiova
Russian Federation	205.452.07030 Boehringer Ingelheim Investigational Site	Arkhangelsk
Russian Federation	205.452.07049 Boehringer Ingelheim Investigational Site	Barnaul
Russian Federation	205.452.07054 Boehringer Ingelheim Investigational Site	Barnaul
Russian Federation	205.452.07053 Boehringer Ingelheim Investigational Site	Chelyabinsk
Russian Federation	205.452.07031 Boehringer Ingelheim Investigational Site	Ekaterinburg
Russian Federation	205.452.07038 Boehringer Ingelheim Investigational Site	Gatchina (Leningradskaya oblast)
Russian Federation	205.452.07036 Boehringer Ingelheim Investigational Site	Irkutsk
Russian Federation	205.452.07001 Boehringer Ingelheim Investigational Site	Ivanovo
Russian Federation	205.452.07023 Boehringer Ingelheim Investigational Site	Kaliningrad
Russian Federation	205.452.07003 Boehringer Ingelheim Investigational Site	Kazan
Russian Federation	205.452.07005 Boehringer Ingelheim Investigational Site	Kazan
Russian Federation	205.452.07007 Boehringer Ingelheim Investigational Site	Kazan
Russian Federation	205.452.07048 Boehringer Ingelheim Investigational Site	Kemerovo
Russian Federation	205.452.07060 Boehringer Ingelheim Investigational Site	Kemerovo
Russian Federation	205.452.07059 Boehringer Ingelheim Investigational Site	Kirov
Russian Federation	205.452.07009 Boehringer Ingelheim Investigational Site	Krasnodar
Russian Federation	205.452.07010 Boehringer Ingelheim Investigational Site	Krasnodar
Russian Federation	205.452.07013 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	205.452.07020 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	205.452.07021 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	205.452.07026 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	205.452.07027 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	205.452.07028 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	205.452.07029 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	205.452.07043 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	205.452.07045 Boehringer Ingelheim Investigational Site	Moscow
Russian Federation	205.452.07004 Boehringer Ingelheim Investigational Site	Murmansk
Russian Federation	205.452.07055 Boehringer Ingelheim Investigational Site	Nizhniy Novgorod
Russian Federation	205.452.07051 Boehringer Ingelheim Investigational Site	Nizhny Novgorod
Russian Federation	205.452.07037 Boehringer Ingelheim Investigational Site	Novosibirsk
Russian Federation	205.452.07040 Boehringer Ingelheim Investigational Site	Novosibirsk
Russian Federation	205.452.07042 Boehringer Ingelheim Investigational Site	Novosibirsk
Russian Federation	205.452.07041 Boehringer Ingelheim Investigational Site	Penza
Russian Federation	205.452.07050 Boehringer Ingelheim Investigational Site	Pskov
Russian Federation	205.452.07015 Boehringer Ingelheim Investigational Site	Rostov-na-Donu
Russian Federation	205.452.07016 Boehringer Ingelheim Investigational Site	Rostov-on-Don
Russian Federation	205.452.07039 Boehringer Ingelheim Investigational Site	Ryazan
Russian Federation	205.452.07034 Boehringer Ingelheim Investigational Site	Samara
Russian Federation	205.452.07047 Boehringer Ingelheim Investigational Site	Saratov
Russian Federation	205.452.07002 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07006 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07011 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07014 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07017 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07018 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07022 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07024 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07025 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07033 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07046 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07052 Boehringer Ingelheim Investigational Site	St. Petersburg
Russian Federation	205.452.07032 Boehringer Ingelheim Investigational Site	Tomsk
Russian Federation	205.452.07035 Boehringer Ingelheim Investigational Site	Tomsk
Russian Federation	205.452.07057 Boehringer Ingelheim Investigational Site	Tomsk
Russian Federation	205.452.07019 Boehringer Ingelheim Investigational Site	Velikiy Novgorod
Russian Federation	205.452.07044 Boehringer Ingelheim Investigational Site	Yaroslavl
Serbia	205.452.38103 Boehringer Ingelheim Investigational Site	Belgrade
Serbia	205.452.38104 Boehringer Ingelheim Investigational Site	Belgrade
Serbia	205.452.38106 Boehringer Ingelheim Investigational Site	Belgrade
Serbia	205.452.38107 Boehringer Ingelheim Investigational Site	Belgrade
Serbia	205.452.38102 Boehringer Ingelheim Investigational Site	Kragujevac
Serbia	205.452.38105 Boehringer Ingelheim Investigational Site	Nis
Serbia	205.452.38101 Boehringer Ingelheim Investigational Site	Sremska Kamenica
Slovakia	205.452.42103 Boehringer Ingelheim Investigational Site	Bardejov
Slovakia	205.452.42107 Boehringer Ingelheim Investigational Site	Bratislava
Slovakia	205.452.42102 Boehringer Ingelheim Investigational Site	Humenne
Slovakia	205.452.42105 Boehringer Ingelheim Investigational Site	Kosice
Slovakia	205.452.42111 Boehringer Ingelheim Investigational Site	Kosice
Slovakia	205.452.42113 Boehringer Ingelheim Investigational Site	Kosice
Slovakia	205.452.42108 Boehringer Ingelheim Investigational Site	Levice
Slovakia	205.452.42109 Boehringer Ingelheim Investigational Site	Martin
Slovakia	205.452.42112 Boehringer Ingelheim Investigational Site	Poprad
Slovakia	205.452.42101 Boehringer Ingelheim Investigational Site	Presov
Slovakia	205.452.42104 Boehringer Ingelheim Investigational Site	Rimavska Sobota
Slovakia	205.452.42106 Boehringer Ingelheim Investigational Site	Spisska Nova Ves
Slovakia	205.452.42110 Boehringer Ingelheim Investigational Site	Sturovo
South Africa	205.452.27013 Boehringer Ingelheim Investigational Site	Amanzimtoti
South Africa	205.452.27002 Boehringer Ingelheim Investigational Site	Bellville
South Africa	205.452.27010 Boehringer Ingelheim Investigational Site	Bloemfontein
South Africa	205.452.27001 Boehringer Ingelheim Investigational Site	Cape Town
South Africa	205.452.27004 Boehringer Ingelheim Investigational Site	Cape Town
South Africa	205.452.27008 Boehringer Ingelheim Investigational Site	Cape Town
South Africa	205.452.27011 Boehringer Ingelheim Investigational Site	Cape Town
South Africa	205.452.27012 Boehringer Ingelheim Investigational Site	Cape Town
South Africa	205.452.27006 Boehringer Ingelheim Investigational Site	Centurion
South Africa	205.452.27003 Boehringer Ingelheim Investigational Site	Durban
South Africa	205.452.27014 Boehringer Ingelheim Investigational Site	Johannesburg
South Africa	205.452.27005 Boehringer Ingelheim Investigational Site	Pretoria
South Africa	205.452.27009 Boehringer Ingelheim Investigational Site	Pretoria
South Africa	205.452.27007 Boehringer Ingelheim Investigational Site	Somerset West
Spain	205.452.34018 Boehringer Ingelheim Investigational Site	Badajoz
Spain	205.452.34021 Boehringer Ingelheim Investigational Site	Badalona (Barcelona)
Spain	205.452.34010 Boehringer Ingelheim Investigational Site	Barcelona
Spain	205.452.34025 Boehringer Ingelheim Investigational Site	Barcelona
Spain	205.452.34015 Boehringer Ingelheim Investigational Site	Cáceres
Spain	205.452.34027 Boehringer Ingelheim Investigational Site	Centelles
Spain	205.452.34016 Boehringer Ingelheim Investigational Site	Elda
Spain	205.452.34008 Boehringer Ingelheim Investigational Site	Hospitalet de Llobregat
Spain	205.452.34026 Boehringer Ingelheim Investigational Site	Lugo
Spain	205.452.34011 Boehringer Ingelheim Investigational Site	Madrid
Spain	205.452.34019 Boehringer Ingelheim Investigational Site	Madrid
Spain	205.452.34020 Boehringer Ingelheim Investigational Site	Málaga
Spain	205.452.34002 Boehringer Ingelheim Investigational Site	Mérida
Spain	205.452.34017 Boehringer Ingelheim Investigational Site	Plasencia
Spain	205.452.34001 Boehringer Ingelheim Investigational Site	Pozuelo de Alarcón
Spain	205.452.34024 Boehringer Ingelheim Investigational Site	San Juan de Alicante
Spain	205.452.34003 Boehringer Ingelheim Investigational Site	Santander
Spain	205.452.34005 Boehringer Ingelheim Investigational Site	Terrassa (Barcelona)
Spain	205.452.34007 Boehringer Ingelheim Investigational Site	Torrevieja
Spain	205.452.34012 Boehringer Ingelheim Investigational Site	Valencia
Spain	205.452.34013 Boehringer Ingelheim Investigational Site	Valladolid
Spain	205.452.34009 Boehringer Ingelheim Investigational Site	Vic (Barcelona)
Spain	205.452.34023 Boehringer Ingelheim Investigational Site	Vilanova i la Geltrú
Spain	205.452.34004 Boehringer Ingelheim Investigational Site	Zaragoza
Sweden	205.452.46005 Boehringer Ingelheim Investigational Site	Brämhult
Sweden	205.452.46014 Boehringer Ingelheim Investigational Site	Eksjö
Sweden	205.452.46013 Boehringer Ingelheim Investigational Site	Göteborg
Sweden	205.452.46012 Boehringer Ingelheim Investigational Site	Gullspång
Sweden	205.452.46001 Boehringer Ingelheim Investigational Site	Höllviken
Sweden	205.452.46008 Boehringer Ingelheim Investigational Site	Järfälla
Sweden	205.452.46009 Boehringer Ingelheim Investigational Site	Kil
Sweden	205.452.46007 Boehringer Ingelheim Investigational Site	Lidingö
Sweden	205.452.46003 Boehringer Ingelheim Investigational Site	Luleå
Sweden	205.452.46006 Boehringer Ingelheim Investigational Site	Örebro
Sweden	205.452.46010 Boehringer Ingelheim Investigational Site	Sigtuna
Sweden	205.452.46002 Boehringer Ingelheim Investigational Site	Solna
Sweden	205.452.46011 Boehringer Ingelheim Investigational Site	Uddevalla
Switzerland	205.452.41003 Boehringer Ingelheim Investigational Site	Ascona
Switzerland	205.452.41004 Boehringer Ingelheim Investigational Site	Basel
Switzerland	205.452.41016 Boehringer Ingelheim Investigational Site	Bern
Switzerland	205.452.41012 Boehringer Ingelheim Investigational Site	Glarus
Switzerland	205.452.41001 Boehringer Ingelheim Investigational Site	Gossau
Switzerland	205.452.41015 Boehringer Ingelheim Investigational Site	Liestal
Switzerland	205.452.41010 Boehringer Ingelheim Investigational Site	Locarno
Switzerland	205.452.41011 Boehringer Ingelheim Investigational Site	Lugano
Switzerland	205.452.41007 Boehringer Ingelheim Investigational Site	Spiez
Switzerland	205.452.41002 Boehringer Ingelheim Investigational Site	St. Gallen
Switzerland	205.452.41009 Boehringer Ingelheim Investigational Site	St. Gallen
Switzerland	205.452.41013 Boehringer Ingelheim Investigational Site	Zürich
Switzerland	205.452.41014 Boehringer Ingelheim Investigational Site	Zürich
Taiwan	205.452.88607 Boehringer Ingelheim Investigational Site	Changhua
Taiwan	205.452.88614 Boehringer Ingelheim Investigational Site	Chia-Yi
Taiwan	205.452.88611 Boehringer Ingelheim Investigational Site	Kaohsiung
Taiwan	205.452.88608 Boehringer Ingelheim Investigational Site	Kaohsiung City
Taiwan	205.452.88609 Boehringer Ingelheim Investigational Site	Kaohsiung City
Taiwan	205.452.88604 Boehringer Ingelheim Investigational Site	New Taipei
Taiwan	205.452.88605 Boehringer Ingelheim Investigational Site	Taichung
Taiwan	205.452.88606 Boehringer Ingelheim Investigational Site	Taichung
Taiwan	205.452.88612 Boehringer Ingelheim Investigational Site	Taichung
Taiwan	205.452.88610 Boehringer Ingelheim Investigational Site	Tainan
Taiwan	205.452.88602 Boehringer Ingelheim Investigational Site	Taipei
Taiwan	205.452.88603 Boehringer Ingelheim Investigational Site	Taipei
Taiwan	205.452.88613 Boehringer Ingelheim Investigational Site	Taipei
Taiwan	205.452.88601 Boehringer Ingelheim Investigational Site	Taoyuan County
Thailand	205.452.66004 Boehringer Ingelheim Investigational Site	Chiang Mai
Thailand	205.452.66003 Boehringer Ingelheim Investigational Site	Hatyai, Songkhla
Thailand	205.452.66002 Boehringer Ingelheim Investigational Site	Khon Kaen
Thailand	205.452.66005 Boehringer Ingelheim Investigational Site	Muang, Phitsanulok
Thailand	205.452.66001 Boehringer Ingelheim Investigational Site	Nonthaburi
Tunisia	205.452.21603 Boehringer Ingelheim Investigational Site	Ariana
Tunisia	205.452.21605 Boehringer Ingelheim Investigational Site	Ariana
Tunisia	205.452.21606 Boehringer Ingelheim Investigational Site	Ariana
Tunisia	205.452.21607 Boehringer Ingelheim Investigational Site	Ariana
Tunisia	205.452.21610 Boehringer Ingelheim Investigational Site	Mahdia
Tunisia	205.452.21609 Boehringer Ingelheim Investigational Site	Monastir
Tunisia	205.452.21608 Boehringer Ingelheim Investigational Site	Nabeul
Tunisia	205.452.21601 Boehringer Ingelheim Investigational Site	Tunis
Tunisia	205.452.21602 Boehringer Ingelheim Investigational Site	Tunis
Tunisia	205.452.21604 Boehringer Ingelheim Investigational Site	Tunis
Turkey	205.452.90001 Boehringer Ingelheim Investigational Site	Adana
Turkey	205.452.90008 Boehringer Ingelheim Investigational Site	Ankara
Turkey	205.452.90013 Boehringer Ingelheim Investigational Site	Ankara
Turkey	205.452.90005 Boehringer Ingelheim Investigational Site	Antalya
Turkey	205.452.90018 Boehringer Ingelheim Investigational Site	Aydin
Turkey	205.452.90003 Boehringer Ingelheim Investigational Site	Bolu
Turkey	205.452.90006 Boehringer Ingelheim Investigational Site	Edirne
Turkey	205.452.90010 Boehringer Ingelheim Investigational Site	Erzurum
Turkey	205.452.90019 Boehringer Ingelheim Investigational Site	Hatay
Turkey	205.452.90017 Boehringer Ingelheim Investigational Site	Istanbul
Turkey	205.452.90020 Boehringer Ingelheim Investigational Site	Istanbul
Turkey	205.452.90021 Boehringer Ingelheim Investigational Site	Istanbul
Turkey	205.452.90015 Boehringer Ingelheim Investigational Site	Izmir
Turkey	205.452.90016 Boehringer Ingelheim Investigational Site	Izmir
Turkey	205.452.90022 Boehringer Ingelheim Investigational Site	Izmir
Turkey	205.452.90007 Boehringer Ingelheim Investigational Site	Malatya
Ukraine	205.452.38028 Boehringer Ingelheim Investigational Site	Crimea
Ukraine	205.452.38024 Boehringer Ingelheim Investigational Site	Dnipropetrovks
Ukraine	205.452.38022 Boehringer Ingelheim Investigational Site	Dnipropetrovsk
Ukraine	205.452.38034 Boehringer Ingelheim Investigational Site	Dnyepropyetrovsk
Ukraine	205.452.38002 Boehringer Ingelheim Investigational Site	Donetsk
Ukraine	205.452.38020 Boehringer Ingelheim Investigational Site	Donetsk
Ukraine	205.452.38011 Boehringer Ingelheim Investigational Site	Ivano-Frankivsk
Ukraine	205.452.38005 Boehringer Ingelheim Investigational Site	Kharkiv
Ukraine	205.452.38001 Boehringer Ingelheim Investigational Site	Kharkov
Ukraine	205.452.38004 Boehringer Ingelheim Investigational Site	Kharkov
Ukraine	205.452.38006 Boehringer Ingelheim Investigational Site	Kharkov
Ukraine	205.452.38008 Boehringer Ingelheim Investigational Site	Kharkov
Ukraine	205.452.38018 Boehringer Ingelheim Investigational Site	Kharkov
Ukraine	205.452.38003 Boehringer Ingelheim Investigational Site	Kiev
Ukraine	205.452.38010 Boehringer Ingelheim Investigational Site	Kiev
Ukraine	205.452.38012 Boehringer Ingelheim Investigational Site	Kiev
Ukraine	205.452.38013 Boehringer Ingelheim Investigational Site	Kiev
Ukraine	205.452.38015 Boehringer Ingelheim Investigational Site	Kiev
Ukraine	205.452.38032 Boehringer Ingelheim Investigational Site	Kiev
Ukraine	205.452.38026 Boehringer Ingelheim Investigational Site	Nikolayev
Ukraine	205.452.38023 Boehringer Ingelheim Investigational Site	Odesa
Ukraine	205.452.38027 Boehringer Ingelheim Investigational Site	Odessa
Ukraine	205.452.38031 Boehringer Ingelheim Investigational Site	Odessa
Ukraine	205.452.38017 Boehringer Ingelheim Investigational Site	Simferopol
Ukraine	205.452.38019 Boehringer Ingelheim Investigational Site	Vinnytsya
Ukraine	205.452.38030 Boehringer Ingelheim Investigational Site	Zaporizhzhya
United Kingdom	205.452.44010 Boehringer Ingelheim Investigational Site	Atherstone
United Kingdom	205.452.44008 Boehringer Ingelheim Investigational Site	Burbage
United Kingdom	205.452.44004 Boehringer Ingelheim Investigational Site	Chertsey
United Kingdom	205.452.44002 Boehringer Ingelheim Investigational Site	Chesterfield
United Kingdom	205.452.44003 Boehringer Ingelheim Investigational Site	Coventry
United Kingdom	205.452.44001 Boehringer Ingelheim Investigational Site	Exeter
United Kingdom	205.452.44007 Boehringer Ingelheim Investigational Site	Fowey
United Kingdom	205.452.44005 Boehringer Ingelheim Investigational Site	Frome
United Kingdom	205.452.44011 Boehringer Ingelheim Investigational Site	Leamington Spa
United Kingdom	205.452.44006 Boehringer Ingelheim Investigational Site	St Just, Penzance
United States	205.452.01079 Boehringer Ingelheim Investigational Site	Abingdon	Virginia
United States	205.452.01061 Boehringer Ingelheim Investigational Site	Albuquerque	New Mexico
United States	205.452.01167 Boehringer Ingelheim Investigational Site	Albuquerque	New Mexico
United States	205.452.01234 Boehringer Ingelheim Investigational Site	Alexandria	Virginia
United States	205.452.01002 Boehringer Ingelheim Investigational Site	Altoona	Pennsylvania
United States	205.452.01302 Boehringer Ingelheim Investigational Site	Anaheim	California
United States	205.452.01070 Boehringer Ingelheim Investigational Site	Anchorage	Alaska
United States	205.452.01340 Boehringer Ingelheim Investigational Site	Anderson	South Carolina
United States	205.452.01270 Boehringer Ingelheim Investigational Site	Ann Arbor	Michigan
United States	205.452.01096 Boehringer Ingelheim Investigational Site	Arlington	Texas
United States	205.452.01330 Boehringer Ingelheim Investigational Site	Arlington Heights	Illinois
United States	205.452.01271 Boehringer Ingelheim Investigational Site	Asheville	North Carolina
United States	205.452.01266 Boehringer Ingelheim Investigational Site	Ashland	Oregon
United States	205.452.01107 Boehringer Ingelheim Investigational Site	Athens	Alabama
United States	205.452.01130 Boehringer Ingelheim Investigational Site	Atlanta	Georgia
United States	205.452.01364 Boehringer Ingelheim Investigational Site	Auburn	Maine
United States	205.452.01047 Boehringer Ingelheim Investigational Site	Austell	Georgia
United States	205.452.01053 Boehringer Ingelheim Investigational Site	Baltimore	Maryland
United States	205.452.01169 Boehringer Ingelheim Investigational Site	Bangor	Maine
United States	205.452.01159 Boehringer Ingelheim Investigational Site	Bayside	New York
United States	205.452.01354 Boehringer Ingelheim Investigational Site	Beaver	Pennsylvania
United States	205.452.01248 Boehringer Ingelheim Investigational Site	Belleville	Illinois
United States	205.452.01150 Boehringer Ingelheim Investigational Site	Bellevue	Nebraska
United States	205.452.01083 Boehringer Ingelheim Investigational Site	Bend	Oregon
United States	205.452.01349 Boehringer Ingelheim Investigational Site	Benzonia	Michigan
United States	205.452.01022 Boehringer Ingelheim Investigational Site	Biddeford	Maine
United States	205.452.01226 Boehringer Ingelheim Investigational Site	Billings	Montana
United States	205.452.01023 Boehringer Ingelheim Investigational Site	Birmingham	Alabama
United States	205.452.01035 Boehringer Ingelheim Investigational Site	Birmingham	Alabama
United States	205.452.01052 Boehringer Ingelheim Investigational Site	Birmingham	Alabama
United States	205.452.01219 Boehringer Ingelheim Investigational Site	Birmingham	Alabama
United States	205.452.01227 Boehringer Ingelheim Investigational Site	Birmingham	Alabama
United States	205.452.01280 Boehringer Ingelheim Investigational Site	Birmingham	Alabama
United States	205.452.01165 Boehringer Ingelheim Investigational Site	Boise	Idaho
United States	205.452.01063 Boehringer Ingelheim Investigational Site	Bowling Green	Kentucky
United States	205.452.01126 Boehringer Ingelheim Investigational Site	Brentwood	Tennessee
United States	205.452.01163 Boehringer Ingelheim Investigational Site	Bronxville	New York
United States	205.452.01347 Boehringer Ingelheim Investigational Site	Brownsburg	Indiana
United States	205.452.01101 Boehringer Ingelheim Investigational Site	Burlington	North Carolina
United States	205.452.01076 Boehringer Ingelheim Investigational Site	Butte	Montana
United States	205.452.01264 Boehringer Ingelheim Investigational Site	Calabash	North Carolina
United States	205.452.01193 Boehringer Ingelheim Investigational Site	Canal Fulton	Ohio
United States	205.452.01143 Boehringer Ingelheim Investigational Site	Carnegie	Pennsylvania
United States	205.452.01374 Boehringer Ingelheim Investigational Site	Centerville	Ohio
United States	205.452.01218 Boehringer Ingelheim Investigational Site	Chandler	Arizona
United States	205.452.01066 Boehringer Ingelheim Investigational Site	Charleston	South Carolina
United States	205.452.01168 Boehringer Ingelheim Investigational Site	Charlotte	North Carolina
United States	205.452.01205 Boehringer Ingelheim Investigational Site	Chaska	Minnesota
United States	205.452.01220 Boehringer Ingelheim Investigational Site	Chattanooga	Tennessee
United States	205.452.01324 Boehringer Ingelheim Investigational Site	Chattanooga	Tennessee
United States	205.452.01365 Boehringer Ingelheim Investigational Site	Chelsea	Michigan
United States	205.452.01014 Boehringer Ingelheim Investigational Site	Chesterfield	Missouri
United States	205.452.01149 Boehringer Ingelheim Investigational Site	Chesterfield	Michigan
United States	205.452.01278 Boehringer Ingelheim Investigational Site	Chicago	Illinois
United States	205.452.01006 Boehringer Ingelheim Investigational Site	Cincinnati	Ohio
United States	205.452.01373 Boehringer Ingelheim Investigational Site	Cincinnati	Ohio
United States	205.452.01011 Boehringer Ingelheim Investigational Site	Clearwater	Florida
United States	205.452.01314 Boehringer Ingelheim Investigational Site	Cleveland	Ohio
United States	205.452.01059 Boehringer Ingelheim Investigational Site	Coeur d'Alene	Idaho
United States	205.452.01049 Boehringer Ingelheim Investigational Site	Colorado Springs	Colorado
United States	205.452.01245 Boehringer Ingelheim Investigational Site	Colorado Springs	Colorado
United States	205.452.01217 Boehringer Ingelheim Investigational Site	Columbia	South Carolina
United States	205.452.01210 Boehringer Ingelheim Investigational Site	Columbus	Ohio
United States	205.452.01232 Boehringer Ingelheim Investigational Site	Columbus	Ohio
United States	205.452.01255 Boehringer Ingelheim Investigational Site	Columbus	Georgia
United States	205.452.01012 Boehringer Ingelheim Investigational Site	Conyers	Georgia
United States	205.452.01194 Boehringer Ingelheim Investigational Site	Cooperstown	New York
United States	205.452.01050 Boehringer Ingelheim Investigational Site	Corsicana	Texas
United States	205.452.01189 Boehringer Ingelheim Investigational Site	Corvallis	Oregon
United States	205.452.01284 Boehringer Ingelheim Investigational Site	Council Bluffs	Iowa
United States	205.452.01267 Boehringer Ingelheim Investigational Site	Cranston	Rhode Island
United States	205.452.01233 Boehringer Ingelheim Investigational Site	Dallas	Texas
United States	205.452.01334 Boehringer Ingelheim Investigational Site	Dallas	Texas
United States	205.452.01199 Boehringer Ingelheim Investigational Site	Danbury	Connecticut
United States	205.452.01065 Boehringer Ingelheim Investigational Site	Danville	Virginia
United States	205.452.01285 Boehringer Ingelheim Investigational Site	Danville	Virginia
United States	205.452.01309 Boehringer Ingelheim Investigational Site	Dayton	Ohio
United States	205.452.01140 Boehringer Ingelheim Investigational Site	Delaware	Ohio
United States	205.452.01351 Boehringer Ingelheim Investigational Site	Denver	Colorado
United States	205.452.01146 Boehringer Ingelheim Investigational Site	Detroit	Michigan
United States	205.452.01371 Boehringer Ingelheim Investigational Site	Downer Grove	Illinois
United States	205.452.01320 Boehringer Ingelheim Investigational Site	Downingtown	Pennsylvania
United States	205.452.01021 Boehringer Ingelheim Investigational Site	Dubuque	Iowa
United States	205.452.01062 Boehringer Ingelheim Investigational Site	Eagle	Idaho
United States	205.452.01303 Boehringer Ingelheim Investigational Site	Easley	South Carolina
United States	205.452.01211 Boehringer Ingelheim Investigational Site	Edina	Minnesota
United States	205.452.01108 Boehringer Ingelheim Investigational Site	Elizabeth City	North Carolina
United States	205.452.01190 Boehringer Ingelheim Investigational Site	Elkridge	Maryland
United States	205.452.01131 Boehringer Ingelheim Investigational Site	Elmira	New York
United States	205.452.01038 Boehringer Ingelheim Investigational Site	Encinitas	California
United States	205.452.01142 Boehringer Ingelheim Investigational Site	Endwell	New York
United States	205.452.01323 Boehringer Ingelheim Investigational Site	Erie	Pennsylvania
United States	205.452.01045 Boehringer Ingelheim Investigational Site	Ettrick	Virginia
United States	205.452.01153 Boehringer Ingelheim Investigational Site	Evansville	Indiana
United States	205.452.01366 Boehringer Ingelheim Investigational Site	Fall River	Massachusetts
United States	205.452.01301 Boehringer Ingelheim Investigational Site	Fishers	Indiana
United States	205.452.01198 Boehringer Ingelheim Investigational Site	Florence	Alabama
United States	205.452.01259 Boehringer Ingelheim Investigational Site	Florence	South Carolina
United States	205.452.01018 Boehringer Ingelheim Investigational Site	Fort Collins	Colorado
United States	205.452.01206 Boehringer Ingelheim Investigational Site	Fort Mitchell	Kentucky
United States	205.452.01057 Boehringer Ingelheim Investigational Site	Fort Worth	Texas
United States	205.452.01181 Boehringer Ingelheim Investigational Site	Fort Worth	Texas
United States	205.452.01272 Boehringer Ingelheim Investigational Site	Fort Worth	Texas
United States	205.452.01313 Boehringer Ingelheim Investigational Site	Fountain Valley	California
United States	205.452.01375 Boehringer Ingelheim Investigational Site	Fountain Valley	California
United States	205.452.01141 Boehringer Ingelheim Investigational Site	Franklin	Indiana
United States	205.452.01187 Boehringer Ingelheim Investigational Site	Fremont	Nebraska
United States	205.452.01104 Boehringer Ingelheim Investigational Site	Fridley	Minnesota
United States	205.452.01074 Boehringer Ingelheim Investigational Site	Fullerton	California
United States	205.452.01013 Boehringer Ingelheim Investigational Site	Gaffney	South Carolina
United States	205.452.01299 Boehringer Ingelheim Investigational Site	Gainesville	Georgia
United States	205.452.01192 Boehringer Ingelheim Investigational Site	Glens Falls	New York
* Note: There are 1191 locations in all - only the first 1000 are shown.

Sponsors *(1)*
Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Denmark, Finland, France, Georgia, Germany, Greece, Guatemala, Hungary, India, Ireland, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, Ukraine, United Kingdom,

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	Time to All-Cause Mortality	Number of patients with all-cause mortality	Up to 3 years	No
Primary	Time to First COPD Exacerbation	Defined as "a complex of lower respiratory events/symptoms (increase of new onset) related to the underlying COPD, with duration of three days or more, requiring a change in treatment" where a "complex of lower respiratory event/symptoms" was defined as having at least two of the following: shortness of breath, sputum production (volume), occurrence of purulent sputum, cough, wheezing, chest tightness and where "a required change in treatment" includes the following:Prescription of antibiotics and/or systemic steroids, and/or a newly prescribed maintenance respiratory medication (i.e., bronchodilators including theophyllines). "Onset of exacerbation" was defined by the onset of first recorded symptom. The "end of exacerbation" was decided by the investigator based on clinical judgement. Exacerbations were classified as follows: Mild:a new prescription of maintenance bronchodilator only Moderate:antibiotics or systemic steroids without hospitalization Severe:hospitalization.	Up to 3 years	No
Secondary	Trough FEV1 Over 120 Weeks (in a Substudy of 1370 Patients)	Trough forced expiratory volume in one second (FEV1) over 120 weeks (in a substudy of 1370 patients)	Up to 3 years	No
Secondary	Number of COPD Exacerbations	The number of COPD exacerbations. COPD exacerbation defined as "a complex of lower respiratory events/symptoms (increase of new onset) related to the underlying COPD, with duration of three days or more, requiring a change in treatment" where a "complex of lower respiratory event/symptoms" was defined as having at least two of the following: shortness of breath, sputum production (volume), occurrence of purulent sputum, cough, wheezing, chest tightness and where "a required change in treatment" includes the following:Prescription of antibiotics and/or systemic steroids, and/or a newly prescribed maintenance respiratory medication (i.e., bronchodilators including theophyllines).	Up to 3 years	No
Secondary	Time to First Hospitalization Associated With COPD Exacerbation	The results presented below are for the patients with hospitalizations due to COPD exacerbations.	Up to 3 years	No
Secondary	Number of Hospitalizations Associated With COPD Exacerbation	Total number of hospitalizations associated with COPD exacerbation.	Up to 3 years	No
Secondary	Time to First Moderate to Severe COPD Exacerbation	COPD exacerbation defined as "a complex of lower respiratory events/symptoms (increase of new onset) related to the underlying COPD, with duration of three days or more, requiring a change in treatment" where a "complex of lower respiratory event/symptoms" was defined as having at least two of the following: shortness of breath, sputum production (volume), occurrence of purulent sputum, cough, wheezing, chest tightness and where "a required change in treatment" includes the following:Prescription of antibiotics and/or systemic steroids, and/or a newly prescribed maintenance respiratory medication (i.e., bronchodilators including theophyllines). Exacerbations classified as follows: Mild:a new prescription of maintenance bronchodilator only Moderate:antibiotics or systemic steroids without hospitalization Severe:hospitalization. Results presented below are number of patients with moderate to severe exacerbations.	Up to 3 years	No
Secondary	Time to Onset of First Major Adverse Cardiovascular Event (MACE)	Time to onset of first major adverse cardiovascular event (MACE). MACE was defined as: Fatal event in the system organ classes of cardiac and vascular disorders, Preferred terms: sudden death, cardiac death, sudden cardiac death, Outcome events of myocardial infarction (serious and non-serious), Outcome events of stroke (serious and non-serious) and Outcome events of TIA (serious and non-serious). The results presented below are for the number of patients with MACE.	Up to 3 years	No
Secondary	Time to Death From Major Adverse Cardiovascular Event (MACE)	The results presented below are number of patients with death from MACE.	Up to 3 years	No

See also
Status	Clinical Trial	Phase
Completed	`NCT05043428` - The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD	N/A
Completed	`NCT00528996` - An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.	Phase 2
Completed	`NCT03740373` - A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate	Phase 1
Completed	`NCT05402020` - Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
Completed	`NCT05393245` - Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
Completed	`NCT04011735` - Re-usable Respimat® Soft MistTM Inhaler Study
Enrolling by invitation	`NCT03075709` - The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
Completed	`NCT03764163` - Image and Model Based Analysis of Lung Disease	Early Phase 1
Completed	`NCT00515268` - Endotoxin Challenge Study For Healthy Men and Women	Phase 1
Completed	`NCT04085302` - TARA Working Prototype Engagement Evaluation: Feasibility Study	N/A
Completed	`NCT03691324` - Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study	N/A
Completed	`NCT02236611` - A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)	Phase 4
Completed	`NCT00153075` - Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)	Phase 4
Completed	`NCT01009463` - A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)	Phase 3
Completed	`NCT01017952` - A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)	Phase 3
Completed	`NCT04882124` - Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD	Phase 2
Completed	`NCT02853123` - Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients	Phase 4
Completed	`NCT02619357` - Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma	Phase 1
Recruiting	`NCT05858463` - High Intensity Interval Training and Muscle Adaptations During PR	N/A
Not yet recruiting	`NCT05032898` - Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II

External Links

Link

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Completed

Administrative data

Study information

Clinical Trial Summary

Recruitment information / eligibility

Study Design

Related Conditions & MeSH terms

Intervention

Locations

Sponsors (1)

Countries where clinical trial is conducted

Outcome

External Links